Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

SPAG11A Inhibitors

The development process for SPAG11A inhibitors would include several stages of screening and optimization. Initially, high-throughput screening of chemical libraries might be used to identify molecules that can bind to SPAG11A. These compounds would then be tested in a series of in vitro assays to evaluate their capacity to inhibit the protein's function. The assays would be designed to measure specific activities associated with SPAG11A, such as binding affinity to its natural substrates or partners, or any enzymatic activities it may possess. Once potential inhibitors are identified, they would undergo a process of hit-to-lead optimization where their chemical structures are modified to improve their effectiveness at inhibiting SPAG11A, as well as to enhance their selectivity, ensuring that they do not significantly affect the function of other proteins.

This optimization process would involve a cycle of synthesis, testing, and analysis known as the structure-activity relationship (SAR) cycle. SAR helps to understand how changes to the chemical structure influence the biological activity of the compounds. Chemists would make targeted modifications to the inhibitor molecules, such as adding or removing functional groups, to improve binding efficiency and specificity. Computational chemistry would play a significant role in this stage, with molecular modeling and docking studies providing insights into the interaction between SPAG11A and the inhibitor compounds at the molecular level. These techniques can predict how adjustments to the inhibitor's structure might impact its ability to fit into the protein's active site or interfere with its function.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

Binds to DNA and inhibits RNA polymerase, which could decrease transcription, potentially affecting SPAG11A expression.

α-Amanitin

23109-05-9sc-202440
sc-202440A
1 mg
5 mg
$269.00
$1050.00
26
(2)

Inhibits RNA polymerase II, leading to reduced mRNA synthesis, which could lower the levels of SPAG11A mRNA.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$41.00
$84.00
$275.00
127
(6)

Inhibits eukaryotic protein synthesis by interfering with ribosome function, which could reduce SPAG11A protein levels.

Puromycin dihydrochloride

58-58-2sc-108071
sc-108071B
sc-108071C
sc-108071A
25 mg
250 mg
1 g
50 mg
$42.00
$214.00
$832.00
$66.00
394
(16)

Causes premature termination of protein synthesis, potentially reducing the levels of many proteins, including SPAG11A.

Emetine

483-18-1sc-470668
sc-470668A
sc-470668B
sc-470668C
1 mg
10 mg
50 mg
100 mg
$440.00
$900.00
$1400.00
$2502.00
(0)

Inhibits protein synthesis by blocking ribosomal translocation, possibly affecting SPAG11A production.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$90.00
$204.00
13
(1)

Inhibits a wide range of gene transcription activities by modulating RNA polymerase II, potentially lowering SPAG11A expression.

Anisomycin

22862-76-6sc-3524
sc-3524A
5 mg
50 mg
$99.00
$259.00
36
(2)

Inhibits peptide bond formation at the ribosome, which could decrease protein synthesis, including that of SPAG11A.

Chloramphenicol

56-75-7sc-3594
25 g
$90.00
10
(1)

Targets bacterial ribosomes but can also affect mitochondrial protein synthesis, potentially impacting SPAG11A.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Inhibits mTOR signaling, which has broad effects on cell growth and protein synthesis, potentially affecting SPAG11A levels.

Homoharringtonine

26833-87-4sc-202652
sc-202652A
sc-202652B
1 mg
5 mg
10 mg
$52.00
$125.00
$182.00
11
(1)

Blocks peptide chain elongation during translation, which could lead to reduced synthesis of proteins including SPAG11A.